Cognitive decline in schizophrenia has long been documented, but the scale and character of dementia in the most severely affected patients has remained poorly mapped — leaving clinicians without a clear framework for prognosis or mechanism. A new study in JAMA Psychiatry begins to fill that gap, and the findings reframe how dementia risk in psychiatric populations should be understood.
The study followed 155 individuals with severe, extremely treatment-resistant schizophrenia (SETRS) — all continuously hospitalized for five or more years at New York State facilities — using the Montreal Cognitive Assessment (MoCA) as the primary cognitive measure. The results were striking: 98.7% of participants scored below the MoCA threshold for mild cognitive impairment, and nearly half (47.1%) fell below a threshold consistent with more pronounced dementia-level impairment. Cognitive, clinical, and genetic profiles were benchmarked against established dementia cohorts from the National Alzheimer Coordinating Center, including Alzheimer's disease, frontotemporal dementia, Lewy body dementia, and vascular dementia, as well as healthy controls. Regression analyses identified which demographic, clinical, and genetic variables most strongly predicted cognitive scores.
What makes this work particularly significant is its comparative design. Rather than treating schizophrenia-associated dementia as a secondary footnote to Alzheimer's research, the study positions it as a distinct clinical entity warranting its own mechanistic inquiry. The 4- to 20-fold elevated dementia rate in schizophrenia relative to the general population — a figure long cited but little interrogated at this depth — now has a richer phenotypic portrait attached to it. Limitations are real: the retrospective design, exclusively hospitalized cohort, and small sample size constrain generalizability to community-dwelling individuals with schizophrenia. The genetic findings, not fully detailed in the excerpt, will be critical for determining whether shared pathways with Alzheimer's or distinct neurobiological routes are responsible. This is an incremental but methodologically careful step toward a field-changing recognition that severe psychiatric illness may itself constitute a dementia risk pathway.